Lazertinib is an oral, potent, and irreversible EGFR TKI that is highly selective for activating (EGFRm) and T790M resistance mutations. In 2024, the US FDA approved the combination of lazertinib and immunotherapy for first-line treatment of NSCLC harbouring the mutation. Research on lazertinib monotherapy is ongoing, highlighting its potential as an alternative treatment option for lung cancer. The primary patent on lazertinib has been granted in many LMICs including India and is expected to expire in 2034. There are secondary patents that may provide further exclusivity until 2038-2041 in many LMICs.